Back to News
May 19, 2026 12:10 PM

Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results

Boston Scientific Corporation (NYSE:BSX) on Tuesday reported positive pivotal trial data for its investigational SEISMIQ 4CE Coronary Intravascular Lithotripsy catheter, with the device meeting both primary safety and effectiveness goals in patients with severely calcified coronary artery disease.

The study evaluated the use of the coronary intravascular lithotripsy (IVL) catheter in patients undergoing percutaneous coronary intervention procedures.

Read Also:

Why Is Boston Scientific Stock Soaring Wednesday?

Trial Met Safety And Effectiveness Endpoints

The trial enrolled 420 patients with severe coronary artery disease.

The primary safety endpoint was achieved with a 93.3% rate of freedom from major adverse cardiac events at 30 days.

The endpoint ...